Oric Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Oric Pharmaceuticals
ORIC Stock  USD 13.88  0.43  3.20%   
Oric Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Oric Pharmaceuticals' valuation are provided below:
Market Capitalization
1.3 B
Earnings Share
(1.71)
We have found one hundred twenty available trending fundamental ratios for Oric Pharmaceuticals, which can be analyzed and compared to other ratios and to its competitors. Investors should ensure to check out all of Oric Pharmaceuticals' recent performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road.
Check Oric Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oric Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.1 M, Interest Expense of 3.2 M or Selling General Administrative of 19.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.18. Oric financial statements analysis is a perfect complement when working with Oric Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Oric Stock
Check out the analysis of Oric Pharmaceuticals Correlation against competitors.
For information on how to trade Oric Stock refer to our How to Trade Oric Stock guide.

Oric Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets239.4 M411 M141.7 M
Slightly volatile
Other Current Liabilities10.9 M13.3 M6.4 M
Slightly volatile
Total Current Liabilities14.2 M20.4 M8.7 M
Slightly volatile
Other Liabilities187.2 K197.1 K1 M
Slightly volatile
Property Plant And Equipment Net6.1 M9.1 M4.5 M
Slightly volatile
Current Deferred Revenue513.4 K627.9 K465.2 K
Slightly volatile
Accounts Payable4 M3.8 M1.3 M
Slightly volatile
Cash58.4 M45.7 M52.7 M
Slightly volatile
Non Current Assets Total128.7 M122.5 M25.9 M
Slightly volatile
Non Currrent Assets Other93.1 K98 K1.7 M
Slightly volatile
Cash And Short Term Investments200.5 M281.5 M118.9 M
Slightly volatile
Common Stock Shares Outstanding92.2 M87.8 M26.1 M
Slightly volatile
Liabilities And Stockholders Equity239.4 M411 M141.7 M
Slightly volatile
Non Current Liabilities Total5.9 M6.2 M10.3 M
Very volatile
Other Current Assets3.8 M7 M2.4 M
Slightly volatile
Other Stockholder Equity1.1 B1.1 B299.7 M
Slightly volatile
Total Liabilities24.2 M26.6 M19.2 M
Slightly volatile
Total Current Assets204.3 M288.5 M121.3 M
Slightly volatile
Common Stock11.6 K11 K3.5 K
Slightly volatile
Property Plant Equipment2.8 M3.7 M2.9 M
Pretty Stable
Capital Surpluse338 M641.5 M214.3 M
Slightly volatile
Property Plant And Equipment Gross7.3 M10.1 M4.7 M
Slightly volatile
Non Current Liabilities Other6 M4.1 M2.6 M
Slightly volatile
Net Working Capital210.6 M268 M121.8 M
Slightly volatile
Common Stock Total Equity4.1 K5.8 K3.1 K
Slightly volatile
Deferred Long Term Liabilities187.2 K197.1 K877 K
Slightly volatile
Short Term Debt2.3 M3.3 M1.3 M
Slightly volatile
Short Term Investments180.2 M235.8 M195 M
Slightly volatile
Short and Long Term Debt Total8.6 M11.6 M4 M
Slightly volatile

Oric Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.1 M1.2 M964.2 K
Slightly volatile
Selling General Administrative19.6 M33.2 M12 M
Slightly volatile
Selling And Marketing Expenses1.1 M1.2 M980.8 K
Slightly volatile
Other Operating Expenses87.4 M143 M56.5 M
Slightly volatile
Research Development67.1 M109.8 M44.1 M
Slightly volatile
Cost Of Revenue1.1 M1.2 M964.2 K
Slightly volatile
Total Operating Expenses86.7 M141.8 M55.8 M
Slightly volatile
Total Other Income Expense Net14.2 M13.5 M3.7 M
Slightly volatile
Net Interest Income3.2 M3 M1.4 M
Slightly volatile
Interest Income3.2 M3 M1.4 M
Slightly volatile
Reconciled Depreciation1.1 M1.2 M968.5 K
Slightly volatile
Non Operating Income Net Other12.8 K13.5 K119.6 K
Slightly volatile

Oric Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation26.3 M25 M7.1 M
Slightly volatile
Begin Period Cash Flow80.7 M59.9 M62.8 M
Slightly volatile
Depreciation1.1 M1.2 M966.2 K
Slightly volatile
Capital Expenditures1 M712 K742.2 K
Slightly volatile
Total Cash From Financing Activities260 M247.7 M68 M
Slightly volatile
End Period Cash Flow58.6 M46.2 M52.9 M
Slightly volatile
Change To Netincome10 M16.7 M6.6 M
Slightly volatile
Sale Purchase Of Stock466 K490.5 K43.4 M
Pretty Stable
Issuance Of Capital Stock125 M244.4 M78.7 M
Slightly volatile
Cash Flows Other Operating880.6 K927 K11.7 M
Slightly volatile
Change To Account Receivables154.4 K173.7 K189.6 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.730.58360.7496
Slightly volatile
Payables Turnover0.30.3191.292
Very volatile
Cash Per Share3.053.206215.1076
Slightly volatile
Days Payables Outstanding1.2 K1.1 K440
Slightly volatile
Income Quality0.940.87560.8924
Slightly volatile
Net Debt To EBITDA0.250.2661.2657
Pretty Stable
Current Ratio17.2814.128713.5342
Slightly volatile
Debt To Equity0.0240.03010.0148
Slightly volatile
Capex Per Share0.00770.00810.213
Slightly volatile
Interest Debt Per Share0.180.13160.0904
Slightly volatile
Debt To Assets0.02150.02810.0134
Slightly volatile
Days Of Payables Outstanding1.2 K1.1 K440
Slightly volatile
Ebt Per Ebit1.050.90530.9668
Pretty Stable
Long Term Debt To Capitalization0.00850.00950.0104
Slightly volatile
Total Debt To Capitalization0.02310.02920.0144
Slightly volatile
Debt Equity Ratio0.0240.03010.0148
Slightly volatile
Quick Ratio17.2814.128713.5342
Slightly volatile
Cash Ratio2.122.23688.7106
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.121.00631.0264
Pretty Stable
Debt Ratio0.02150.02810.0134
Slightly volatile

Oric Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap476.6 M646.3 M498.1 M
Slightly volatile
Enterprise Value457.7 M615.6 M482.3 M
Slightly volatile

Oric Fundamental Market Drivers

Oric Upcoming Events

21st of March 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Oric Pharmaceuticals Financial Statements

Oric Pharmaceuticals stakeholders use historical fundamental indicators, such as Oric Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Oric Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Oric Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Oric Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Oric Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue627.9 K513.4 K
Cost Of Revenue1.2 M1.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
When determining whether Oric Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oric Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oric Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oric Pharmaceuticals Stock:
How To Invest In Oric
Details
Is Oric Stock a good investment?
Details
What is Oric Pharmaceuticals' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Oric Pharmaceuticals Correlation against competitors.
For information on how to trade Oric Stock refer to our How to Trade Oric Stock guide.
You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Will Biotechnology sector continue expanding? Could Oric diversify its offerings? Factors like these will boost the valuation of Oric Pharmaceuticals. Anticipated expansion of Oric directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Oric Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(1.71)
Return On Assets
(0.26)
Return On Equity
(0.41)
Oric Pharmaceuticals's market price often diverges from its book value, the accounting figure shown on Oric's balance sheet. Smart investors calculate Oric Pharmaceuticals' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Oric Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between Oric Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Oric Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Oric Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY